Pharmacotherapy of essential tremor.

Article Details

Citation

Hedera P, Cibulcik F, Davis TL

Pharmacotherapy of essential tremor.

J Cent Nerv Syst Dis. 2013 Dec 22;5:43-55. doi: 10.4137/JCNSD.S6561.

PubMed ID
24385718 [ View in PubMed
]
Abstract

Essential tremor (ET) is a common movement disorder but its pathogenesis remains poorly understood. This has limited the development of effective pharmacotherapy. The current therapeutic armamentaria for ET represent the product of careful clinical observation rather than targeted molecular modeling. Here we review their pharmacokinetics, metabolism, dosing, and adverse effect profiles and propose a treatment algorithm. We also discuss the concept of medically refractory tremor, as therapeutic trials should be limited unless invasive therapy is contraindicated or not desired by patients.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
PrimidoneGABA(A) Receptor (Protein Group)Protein groupHumans
Yes
Positive allosteric modulator
Details
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
PrimidoneCytochrome P450 1A2ProteinHumans
Unknown
Inducer
Details
PrimidoneCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Inducer
Details
PrimidoneCytochrome P450 3A4ProteinHumans
Unknown
Inducer
Details
Drug Interactions
DrugsInteraction
Amobarbital
Primidone
The risk or severity of adverse effects can be increased when Primidone is combined with Amobarbital.
Amobarbital
Methylphenobarbital
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.
Amobarbital
Phenobarbital
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Amobarbital.
Butabarbital
Primidone
The risk or severity of adverse effects can be increased when Primidone is combined with Butabarbital.
Butabarbital
Methylphenobarbital
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butabarbital.